Another recent study utilized inhibition of Exportin 1 (XPO1) to decrease expression of Mcl-1.110 XPO1 is a nuclear exporter that is overexpressed in AML cells and its inhibition has been correlated with decreased expression of Mcl-1.111 This study found that inhibition of XPO1 via Selinexor (KPT-330) reduced Mcl-1 expression and the combination of selinexor and venetoclax were found to be synergistic in AML cell lines and primary patient samples.110 There is currently a phase Ib trial of selinexor in combination with venetoclax for AML, DLBCL, and NHL (NCT03955783). This evidence concerns the gene MCL1 and non-Hodgkin lymphoma.